These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 33565150)

  • 1. Estimation of sodium-glucose cotransporter 2 inhibitor-related genital and urinary tract infections via electronic medical record-based common data model.
    Ko S; Kim H; Shinn J; Byeon SJ; Choi JH; Kim HS
    J Clin Pharm Ther; 2021 Aug; 46(4):975-983. PubMed ID: 33565150
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative Genitourinary Safety of In-class Sodium-Glucose Cotransporter-2 Inhibitors among Patients with Heart Failure with Preserved Ejection Fraction: A Cohort Study.
    Riaz M; Guo J; Smith SM; Dietrich EA; Winchester DE; Park H
    Am J Cardiovasc Drugs; 2024 May; 24(3):455-464. PubMed ID: 38691312
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Adverse Events Associated with Sodium-Glucose Cotransporter 2 Inhibitors: A Meta-Analysis Involving 10 Randomized Clinical Trials and 71 553 Individuals.
    Lin DS; Lee JK; Chen WJ
    J Clin Endocrinol Metab; 2021 Jun; 106(7):2133-2145. PubMed ID: 33895840
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk factors of first and recurrent genitourinary tract infection in patients with type 2 diabetes treated with SGLT2 inhibitors: A retrospective cohort study.
    Lin YH; Lin CH; Huang YY; Tai AS; Fu SC; Chen ST; Lin SH
    Diabetes Res Clin Pract; 2022 Apr; 186():109816. PubMed ID: 35247527
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sodium-glucose cotransporter 2 inhibitors as an add-on therapy to insulin for type 1 diabetes mellitus: Meta-analysis of randomized controlled trials.
    Rao L; Ren C; Luo S; Huang C; Li X
    Acta Diabetol; 2021 Jul; 58(7):869-880. PubMed ID: 33651228
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence of Bacterial Urinary Tract Infection Among Patients With Type 2 Diabetes Mellitus on Sodium-Glucose Cotransporter-2 Inhibitors: A Prospective Real-World Setting Study.
    Ferwani P; Maldar A; Shah N; Chauhan P; Chadha M
    J ASEAN Fed Endocr Soc; 2022; 37(2):5-8. PubMed ID: 36578886
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of sodium-glucose cotransporter-2 inhibitors and urinary tract infections in type 2 diabetes patients: a systematic review.
    Figueiredo IR; Rose SCP; Freire NB; Patrocínio MS; Pierdoná N; Bittencourt RJ
    Rev Assoc Med Bras (1992); 2019 Feb; 65(2):246-252. PubMed ID: 30892451
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Urinary tract infections and genital mycotic infections associated with SGLT‑2 inhibitors: an analysis of the FDA Adverse Event Reporting System.
    Yang T; Zhou Y; Cui Y
    Expert Opin Drug Saf; 2024 Aug; 23(8):1035-1040. PubMed ID: 38009230
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Five comparative cohorts to assess the risk of genital tract infections associated with sodium-glucose cotransporter-2 inhibitors initiation in type 2 diabetes mellitus.
    Alkabbani W; Zongo A; Minhas-Sandhu JK; Eurich DT; Shah BR; Alsabbagh MW; Gamble JM
    Diabet Med; 2022 Aug; 39(8):e14858. PubMed ID: 35460294
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sodium-Glucose Cotransporter-2 Inhibitors and the Risk for Severe Urinary Tract Infections: A Population-Based Cohort Study.
    Dave CV; Schneeweiss S; Kim D; Fralick M; Tong A; Patorno E
    Ann Intern Med; 2019 Aug; 171(4):248-256. PubMed ID: 31357213
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Generalizability of Cardiovascular Safety Trials on SGLT2 Inhibitors to the Real World: Implications for Clinical Practice.
    Nicolucci A; Candido R; Cucinotta D; Graziano G; Rocca A; Rossi MC; Tuccinardi F; Manicardi V
    Adv Ther; 2019 Oct; 36(10):2895-2909. PubMed ID: 31410779
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sodium-Glucose Cotransporter-2 Inhibitors and Urinary Tract Infections: A Propensity Score-matched Population-based Cohort Study.
    Alkabbani W; Zongo A; Minhas-Sandhu JK; Eurich DT; Shah BR; Alsabbagh MW; Gamble JM
    Can J Diabetes; 2022 Jun; 46(4):392-403.e13. PubMed ID: 35513988
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sodium-glucose cotransporter 2 inhibitors for treatment of diabetes mellitus after kidney transplantation.
    Lemke A; Brokmeier HM; Leung SB; Mara KC; Mour GK; Wadei HM; Hill JM; Stegall M; Kudva YC; Shah P; Kukla A
    Clin Transplant; 2022 Aug; 36(8):e14718. PubMed ID: 35593882
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genito-urinary infectious adverse events related to sodium glucose cotransporter-2 inhibitors: a network meta-analysis and meta-regression.
    Sridharan K; Sivaramakrishnan G
    Expert Rev Clin Pharmacol; 2024; 17(5-6):515-524. PubMed ID: 38733378
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discontinuation rate and reason for discontinuation after sodium-glucose cotransporter 2 inhibitor prescription in real clinical practice.
    Kim H; Lee SH; Cho JH; Lee H; Yim HW; Yoon KH; Kim HS
    J Clin Pharm Ther; 2020 Dec; 45(6):1271-1277. PubMed ID: 32533743
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk of genital and urinary tract infections associated with SGLT-2 inhibitors as an add-on therapy to metformin in patients with type 2 diabetes mellitus: A retrospective cohort study in Korea.
    Yang H; Choi E; Park E; Na E; Chung SY; Kim B; Han SY
    Pharmacol Res Perspect; 2022 Feb; 10(1):e00910. PubMed ID: 35005849
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sodium-glucose cotransporter-2 inhibitors increase urinary tract infections?-a cross sectional analysis of a nationwide Japanese claims database.
    Anan G; Kikuchi D; Omae K; Hirose T; Okada K; Mori T
    Endocr J; 2023 Nov; 70(11):1103-1107. PubMed ID: 37673640
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Urinary tract and genital infections in patients with type 2 diabetes treated with sodium-glucose co-transporter 2 inhibitors: A meta-analysis of randomized controlled trials.
    Li D; Wang T; Shen S; Fang Z; Dong Y; Tang H
    Diabetes Obes Metab; 2017 Mar; 19(3):348-355. PubMed ID: 27862830
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genitourinary infections in diabetic patients in the new era of diabetes therapy with sodium-glucose cotransporter-2 inhibitors.
    Rizzi M; Trevisan R
    Nutr Metab Cardiovasc Dis; 2016 Nov; 26(11):963-970. PubMed ID: 27514605
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adoption of New Glucose-Lowering Medications in the U.S.-The Case of SGLT2 Inhibitors: Nationwide Cohort Study.
    McCoy RG; Dykhoff HJ; Sangaralingham L; Ross JS; Karaca-Mandic P; Montori VM; Shah ND
    Diabetes Technol Ther; 2019 Dec; 21(12):702-712. PubMed ID: 31418588
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.